Jonathan Rosenberg, ESMO 2022: Study EV-103 Cohort K – Enfortumab vedotin in combination with pembrolizumab in locally advanced or metastatic urothelial cancer
As there is a current need for effective and tolerable first line treatment options in patients with locally advanced or metastatic urothelial cancer (la/mUC), Dr Jonathan Rosenberg (Memorial Sloan Kettering Cancer Center, New York, NY, USA) joins touchONCOLOGY to discuss the positive results from Study EV-103 Cohort K. The study data supports ongoing investigations of first line enfortumab vedotin monotherapy or in combination with pembrolizumab in patients with la/mUC who have a high unmet need. Dr Rosenberg also highlights further clinical trial that are ongoing for the treatment of la/mUC.
The abstract entitled ‘Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)‘ Abstract LBA73, was presented at European Society for Medical Oncology (ESMO) 2022.
Questions:
- What are the major unmet needs in the first-line treatment of locally advanced or metastatic urothelial cancer? (0:13)
- What is the rationale for investigating the combination of enfortumab vedotin and pembrolizumab in this treatment setting? (1:08)
- What were the design and eligibility criteria of Study EV-103? (2:08)
- What were the efficacy and safety findings of the study? (3:03)
- What further investigations of this combined therapy are planned? (4:05)
Disclosures: Jonathan Rosenberg is a consultant for Astellas, Seagen, Gilead, and Merck; receives grant/research support from Astellas, and Seagen; is on the advisory board for Astellas, Seagen, Gilead, and Merck; and receives honoraria/honorarium from Pfizer, and EMD-Serono.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.
